When combined with chemotherapeutic agents for HER2-positive breast cancer (neratinib or trastuzumab), HER2-TRIM-ing enhanced drug efficacy and the levels of downstream molecules, p-ERK and p-AKT further decreased, validating the therapeutic potential of TRIM-ing technology. The gene discussed is TRAT1; the disease is breast carcinoma.